# Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia

> **NCT01456182** · PHASE1 · WITHDRAWN · sponsor: **Afexa Life Sciences Inc**

## Conditions studied

- Leukemia, Lymphocytic, Chronic, B-Cell

## Interventions

- **DRUG:** AFX-2
- **DRUG:** AFX-2
- **DRUG:** AFX-2
- **DRUG:** AFX-2
- **DRUG:** AFX-2

## Key facts

- **NCT ID:** NCT01456182
- **Lead sponsor:** Afexa Life Sciences Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-12
- **Primary completion:** 2013-03
- **Final completion:** 2013-05
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01456182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01456182, "Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01456182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*